Holen Sie sich die Stockscreener-App
1.10
0.92%
0.01
Handel nachbörslich:
1.07
-0.03
-2.73%
Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten
Volume Summary: Is Estrella Immunopharma Inc currently under institutional pressureJuly 2025 Momentum & Low Volatility Stock Suggestions - baoquankhu1.vn
ESLAW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ESLA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ESLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
What’s next for Estrella Immunopharma Inc. stockJuly 2025 Decliners & Accurate Entry and Exit Point Alerts - mfd.ru
Travel Stocks: Is Estrella Immunopharma Inc part of any ETFWeekly Investment Recap & Weekly Momentum Picks - baoquankhu1.vn
Will Estrella Immunopharma Inc. benefit from government policyJuly 2025 Trade Ideas & Step-by-Step Swing Trade Plans - mfd.ru
Can Estrella Immunopharma Inc. sustain its profitabilityMarket Trend Summary & Short-Term Trading Opportunity Alerts - mfd.ru
Why Estrella Immunopharma Inc. stock is recommended by analystsMarket Movement Recap & Consistent Income Trade Ideas - mfd.ru
ESLA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Portfolio Update: Will Estrella Immunopharma Inc benefit from government policy2025 Growth vs Value & Accurate Intraday Trade Tips - baoquankhu1.vn
Estrella reports 100% complete response rate in lymphoma trial By Investing.com - Investing.com South Africa
Merger Talk: Is INFA a strong growth stock2025 Dividend Review & Fast Gain Stock Trading Tips - baoquankhu1.vn
ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHL - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for Estrella Immunopharma (NASDAQ:ESLA) - MarketBeat
Estrella Immunopharma Reports Positive STARLIGHT-1 Trial Results - Intellectia AI
Estrella reports 100% complete response rate in lymphoma trial - Investing.com
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR® - Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT(R) & CIBMTR(R) - marketscreener.com
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR - BioSpace
Estrella to present phase 1 data on CD19-targeted cell therapy - Investing.com Canada
Estrella to present phase 1 data on CD19-targeted cell therapy By Investing.com - Investing.com South Africa
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR® - Yahoo Finance
Market Moves: Does Estrella Immunopharma Inc stock have upside surprise potentialBear Alert & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Market Recap: Should I invest in Marvell Technology Inc before earnings2025 Investor Takeaways & Short-Term Swing Trade Alerts - baoquankhu1.vn
ESLA Analyst Rating: Target Price Cut by 50% to $8 | ESLA Stock News - GuruFocus
Rally Mode: How much upside does Estrella Immunopharma Inc have2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
How much upside does Estrella Immunopharma Inc have2025 Risk Factors & High Accuracy Swing Trade Signals - baoquankhu1.vn
Is Estrella Immunopharma Inc. stock overvalued or fairly pricedWeekly Stock Report & Daily Volume Surge Signals - bollywoodhelpline.com
Panic Selling: Is Estrella Immunopharma Inc stock a hidden gemWeekly Profit Analysis & Breakout Confirmation Trade Signals - baoquankhu1.vn
Market Outlook: Will Estrella Immunopharma Inc benefit from government policyJuly 2025 Price Swings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting By Investing.com - Investing.com India
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting - Investing.com
Estrella Immunopharma Receives Nasdaq Non-Compliance Notice - TipRanks
Estrella Immunopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Day Trade: What insider trading reveals about Estrella Immunopharma Inc stock2025 Investor Takeaways & Expert Curated Trade Setups - Bộ Nội Vụ
Is Estrella Immunopharma Inc. stock a good choice for value investors2025 Dividend Review & Fast Gain Swing Alerts - Улправда
How Estrella Immunopharma Inc. stock trades during market volatilityWeekly Trend Recap & Safe Entry Trade Reports - ulpravda.ru
How risky is Estrella Immunopharma Inc. stock nowPortfolio Value Summary & Technical Buy Zone Confirmations - ulpravda.ru
Estrella Immunopharma, Inc.Warrant (NQ: ESLAW - FinancialContent
Is Estrella Immunopharma Inc. stock a smart buy before Fed meetingWeekly Volume Report & Long-Term Growth Stock Strategies - Улправда
Can Estrella Immunopharma Inc. stock sustain market leadershipWatch List & Short-Term Trading Alerts - ulpravda.ru
Is Estrella Immunopharma Inc. stock attractive for passive investors2025 Geopolitical Influence & Accurate Intraday Trading Signals - ulpravda.ru
Published on: 2026-01-07 23:18:22 - Улправда
How interest rate cuts could boost Estrella Immunopharma Inc. stockSector Leadership Analysis & Small Capital Trading Growth - Улправда
Estrella Immunopharma Secures $8 Million in Funding to Advance Cancer Therapy Programs - citybuzz -
Estrella Immunopharma completes $8M direct offering financing - TipRanks
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement - MEXC
Estrella Immunopharma Signs Multiple Material Agreements - TradingView
Estrella Immunopharma closes $8 million registered direct offering - Investing.com
Estrella Immunopharma closes $8 million registered direct offering By Investing.com - Investing.com India
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):